Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 376-384

  Foon, Kenneth A ^a   Lutzky, Jose ^a   Baral, Rathindra N ^a   Yannelli, John R ^a   Hutchins, Laura ^a   Teitelbaum, April ^a   Kashala, Oscar L ^a   Das, Ruma ^a   Garrison, Juanita ^a   Reisfeld, Ralph A ^a   Bhattacharya Chatterjee, Malaya ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; GANGLIOSIDE GD2; TRIGEM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; MALE; MELANOMA; PRIORITY JOURNAL; SKIN IRRITATION;

EID: 0033958915     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.376     Document Type: Article

References (35)

1. Hamilton WB, Helling F, Lloyd KO, et al: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53:566-573, 1993
2. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. Cancer 63:1166-1174, 1989
3. Livingston PO, Wong GYC, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
4. Livingston PO, Ritter F, Srivastava P, et al: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050, 1984
5. Livingston PO, Natoli EJ Jr, Calves MJ, et al: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 84:2911-2915, 1987
6. Lindenmann J: Speculations on idiotypes and homebodies. Ann Immunol (Paris) 124:171-184, 1973
7. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373-389, 1974
8. Chapman PB, Livingston PO, Morrison ME, et al: Immunization of melanoma patients with anti-idiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: Pilot trials using no immunological adjuvant. Vaccine Res 3:59-69, 1994
9. McCaffery M, Yao T-J, Williams L, et al: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2:679-686, 1996
10. Bhattacharya-Chatterjee M, Pride MW, Seon BK, et al: Idiotype vaccines against human T cell acute lymphoblastic leukemia (TALL): I. Generations and characterizations of biologically active monoclonal anti-idiotypes. J Immunol 5:562-573, 1987
11. Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, et al: Idiotype vaccines against T-cell leukemia: II. Generation and characterization of monoclonal idiotype cascade (Ab1, Ab2 and Ab3). J Immunol 141:1398-1403, 1988
12. Foon KA, Oseroff AR, Vaickus L, et al: Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1:1285-1294, 1995
13. Foon KA, Chakraborty M, John WJ, et al: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype vaccine. J Clin Invest 96:334-342, 1995
14. Foon KA, John WJ, Chakraborty M, et al: Clinical and immune responses in resected colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17:2889-2895, 1999
15. Sen G, Chakraborty M, Foon KA, et al: Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J Immunother 21:75-83, 1998
16. Sen G, Chakraborty M, Foon KA, et al: Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res 3:1969-1976, 1997
17. Foon K, Sen G, Hutchins L, et al: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4:1117-1124, 1998
18. Mujoo K, Kipps TJ, Yang HM, et al: Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49:2857-2861, 1989
19. Yao T-J, Meyers M, Livingston PO, et al: Immunization of melanoma patients with BEC2-keyhold limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5:77-81, 1999
20. Quan WDY, Dean GE, Spears L, et al: Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 15:2103-2110, 1997
21. Mittelman A, Chen ZJ, Kageshita T, et al: Active specific immunotherapy in patients with melanoma: A clinical trial with mouse anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies. J Clin Invest 86:2136-2144, 1990
22. Mittelman A, Chen ZJ, Yang H, et al: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 89:466-470, 1992
23. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998
24. Cheung NKV, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
25. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992
26. Keilholz U, Goey S, Punt C, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the Eurpoean Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588, 1997
27. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083-2090, 1996
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
29. Keilholz U, Conradt C, Legha S, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
30. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacabazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 16:1743-1751, 1998
31. Richards JM, Gale D, Mehta N, et al: Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma. J Clin Oncol 17:651-657, 1999
32. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
33. Cheresh DA, Klier FG: Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol 102: 1887-1897, 1986
34. Kleinman HK, Martin GR, Fishman PH: Ganglioside inhibition of fibronectin-mediated cell adhesion to collagen. Proc Natl Acad Sci USA 76:3367-3371, 1979
35. Perkins RM, Kellie S, Patel B, et al: Gangliosides as receptors for fibronectin. Exp Cell Res 141:321-343, 1982